Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib for CNS events in HER2-positive breast cancer with brain metastases
2020-000824-21Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neratinib in breast cancer and brain metastases, sponsored by Institut Jules Bordet. Primary endpoint: Efficacy on brain metastases (RECIST 1.1). Started Jun 2021; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on 2020-000824-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000824-21.